A key benefit of allogeneic cell therapy is that it provides a substantial and economical cost structure, increasing the ability to treat larger patient populations. As allogeneic cell therapy continues its exponential growth, a scale-appropriate model in early development stages for clinical trials, whilst aiding a smooth transition to large-scale cell manufacturing when necessary, is required.

During this webinar, our experts discuss how to achieve your therapeutic and commercial goals utilizing a tried-and-tested standardized approach, combined with the latest technology and reliable analytics.

You will learn about:

  • Challenges associated with allogeneic cell therapy manufacturing
  • How to successfully move through the product lifecycle using the latest technology combined with a tried-and-tested standardized approach
  • How a stirred tank bioreactor platform can enable the transition to large-scale cell manufacturing designed to treat larger patient populations

Speakers: Inbar Friedrich Ben-Nun, Director CGT Research and Development; Marcos Langtry, Head of Commercial Development Allogeneic; Krishna Panchalingam, Associate Director Development Services CGT

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center